Abstract: A semiconductor device includes a substrate, a channel layer, a first barrier layer, a source/drain contact, and a gate layer. The channel layer is on the substrate. The first barrier layer is on the channel layer and the thickness of the first barrier layer is less than 6 nm. The source/drain contact is on the first barrier layer and is directly contact with the first barrier layer. The gate layer is over the first barrier layer.

Abstract: A high electron mobility transistor includes a growth substrate, a lattice matching layer, an back-barrier layer, an electron blocking layer, a channel layer, an active layer, a source, a gate, and a drain. The lattice matching layer and the back-barrier layer are formed on the growth substrate. The back-barrier layer includes GaN doped with C. The electron blocking layer is formed on the back-barrier layer. The electron blocking layer includes AlGaN, wherein the doping percent of Al atoms of the AlGaN is 3˜5% and the doping percent of Ga atoms of the AlGaN is 95˜97%. The electron blocking layer has a thickness of 2˜5 nm. The channel layer and the active layer are formed on the electron blocking layer. The source, the gate, and the drain are formed on the active layer.

Abstract: A high electron mobility transistor and a method for fabricating the same is disclosed. Firstly, a lattice matching layer, a channel layer, and an AlGaN layer are sequentially formed on a growth substrate. The AlGaN layer includes a first area, a second area, and a third area, wherein the second area is located between the first area and the third area. Then, an insulation block is formed on the second area of the AlGaN layer and two GaN blocks are respectively formed on the first area and the third area of the AlGaN layer. Two InAlGaN blocks are respectively formed on the GaN blocks and the insulation block is removed. Finally, a gate is formed to interfere the second area of the AlGaN layer and a source and a drain are respectively formed on the InAlGaN blocks.

Abstract: Provided herein are compositions comprising CXCR1/CXCR2 inhibitors as well as methods of using the CXCR1/CXCR2 inhibitors disclosed herein. In embodiments, provided are methods of treating myelofibrosis, methods of decreasing bone marrow fibrosis, methods of reducing the interaction of IL-8 to CXCR1 and/or CXCR2, and methods of reducing the activity or and/or signaling through CXCR1 and/or CXCR by administering to a subject in need thereof an effective amount of a CXCR1/CXCR2 inhibitor disclosed herein.

Abstract: Aspects of the subject disclosure may include, for example, executing an OTT application; and providing an API that enables the OTT application to connect with a native SIP stack of the device, where the OTT application negotiates with a network server for one or more QoS parameters for a communication service provided via the OTT application. Other embodiments are disclosed.

Abstract: Aspects of the subject disclosure may include, for example, generating prioritized lists of OTT applications for end user devices, exchanging or otherwise providing the prioritized list(s) to enable analysis and comparison resulting in a selection of an OTT application, and establishing a communication service via the selected OTT application between the end user devices. Other embodiments are disclosed.

Abstract: Aspects of the subject disclosure may include, for example, a method in which a processing system creates a network element by consolidating a control plane including a combination of a plurality of 5G control plane functions and a plurality of IMS control plane functions with an associated user plane including a combination of a 5G user plane function (UPF) and one or more IMS user plane functions. The method also includes deploying the network element at a network edge of the service provider network, receiving a request from a user endpoint (UE) device for a network service, and attaching the UE to the network element. The network element is configured to facilitate providing the requested network service. Other embodiments are disclosed.

Abstract: An example method facilitates modification and generation of User Interface (UI) display screens for webpages and web applications, such as process-based software applications. The example method includes receiving a first signal to access a webpage that includes a static UI display screen for a web application; serving the webpage in response to the signal; detecting the dynamic configuration functionality associated with the webpage, wherein the configuration functionality includes code and UI metadata provided in or with a dynamic layout file, the code and UI metadata including one or more rules and specifications for configuring schema used to generate rendering instructions for the dynamic part of the webpage.

Abstract: Aspects of the subject disclosure may include, for example, a device in which a processing system defines service attributes for a function of an internet multimedia subsystem (IMS) core; the function is dedicated for providing a service to a user endpoint (UE) device. The processing system facilitates constructing a resource profile of the IMS core that includes the function; registering the function at a network repository function (NRF) associated with the IMS core; discovering the function from the NRF; obtaining a service requirement of the UE; and matching the service requirement with the service attributes in accordance with matching criteria. Other embodiments are disclosed.

Abstract: A method for bundling network functions as a single microservice in a cloud environment. A service deployment manager may acquire subscriber location information associated with a subscriber or a subscriber profile associated with the subscriber. Moreover, the service deployment manager may utilize the subscriber location information or the subscriber profile to select a cloud location. For example, the cloud location may be based on load, geographical proximity, service profile, etc.

Abstract: Provided are a whole bacteria capsule, a preparation method therefor and a use thereof. The preparation method comprises the steps of: (1) screening fecal bacteria donors using high-throughput sequencing; (2) collecting feces of the fecal bacteria donors screened in step (1), and preparing a fecal bacterial liquid; and (3) mixing the fecal bacterial liquid prepared in step (2) with a freeze-drying protective agent, cooling, freezing and vacuum-drying the mixture, and loading the freeze-dried feces bacteria powder obtained into a capsule shell to obtain the whole bacteria capsule. By screening the fecal bacteria donors using high-throughput sequencing, fecal bacteria donors can be quickly screened for different fecal bacteria receptors, and the whole bacteria capsule prepared can accurately match with the fecal bacteria receptors.

Abstract: Described herein are cell lines for recombinant adeno-associated virus (AAV) production, cell lines for AAV-implemented protein production, and cell lines for use in titering AAV; methods of making each of those cell lines; and methods of using each of those cell lines. In some aspects, the cell lines disclosed herein may be used in a manufacturing process that is seed virus-free, helper virus-free, and transfection-free that uses synthetic elements to control viral genes in a stable cell line.

Abstract: The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceutical compositions comprising the cyclic cyanoenone derivatives of Formula (I) and to their use in therapy.

Abstract: Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.

Abstract: The present invention provides implementation and communication methods, an apparatus and a system of a virtual subscriber identity module. The implementation method includes: receiving a VSIM application request sent by a terminal, where the VSIM application request carries an identifier of a VSIM desired by the terminal; obtaining corresponding VSIM installation information according to the identifier of the desired VSIM; and sending the VSIM installation information to the terminal, so that the terminal installs the VSIM according to the VSIM installation information. The embodiments of the present invention effectively solve a problem where an existing mobile operator network does not support the VSIM, and provide an effective and convenient operation scheme for an existing domestic or international roaming service.

Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Za, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.

Abstract: A display panel has a plurality of pixel areas and a peripheral area surrounding the pixel areas, and includes a substrate, at least two planarization layers, a plurality of pads, a first dummy pattern, and a plurality of light-emitting devices. The substrate has a first substrate edge extending in a first direction. The at least two planarization layers are disposed on the substrate. The pads are disposed on the at least two planarization layers, and are located in the pixel areas. The pads include at least one first edge pad closest to the first substrate edge. The first dummy pattern is disposed on the at least two planarization layers, and extends in the peripheral area between the at least one first edge pad and the first substrate edge. The light-emitting devices are electrically connected to the pads.

Abstract: A sensor using ultrasound to detect presence and nature of analyte includes an ultrasonic element and a receptor thereon. The ultrasonic element includes a first electrode, a second electrode facing and spaced apart from the first electrode, an insulating layer between the first electrode and the second electrode, and a vibrating film between the insulating layer and the first electrode. The vibrating film carries the first electrode. A cavity is formed between the vibrating film and the insulating layer. The receptor is on a side of the first electrode away from the second electrode. The receptor can combine with a target substance in a test analyte. When the first electrode and the second electrode are applied with different voltages, certain ultrasound frequencies are generated as the vibrating film vibrates, and the presence and weight of different target substances are indicated by the changes in resonance.

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.